Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. due to allegations of deceptive promotion and sale of illegitimate versions of Wegovy®, leading to a significant drop in the company's stock price [2][3]. Group 1: Allegations and Impact - Hims & Hers Health, Inc. announced a collaboration with Novo Nordisk on April 29, 2025, to sell Wegovy® on its platform [2]. - Novo Nordisk terminated its partnership with Hims on June 23, 2025, citing deceptive practices that jeopardized patient safety, resulting in a 34.6% decline in Hims' share price, closing at $41.98 [2]. - The lawsuit claims that Hims failed to disclose its engagement in selling illegitimate versions of Wegovy® and the risk of partnership termination with Novo Nordisk [3]. Group 2: Legal Proceedings - Shareholders interested in leading the class action must file a motion by August 25, 2025, and can remain absent class members if they choose not to participate [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses [5].

Core Viewpoint - A class action lawsuit has been filed against Petco Health and Wellness Company, Inc. for allegedly misleading investors about its business prospects during the pandemic [1][2]. Group 1: Allegations - The lawsuit claims that Petco's pandemic-related growth was unsustainable and that its business model focused on premium pet food was overstated [2]. - It is alleged that the company downplayed the severity of issues affecting its business and the necessary changes to address these issues [2]. - The complaint states that Petco overstated its ability to achieve sustainable and profitable growth, leading to a decline in stock price when the truth was revealed [2]. Group 2: Class Action Participation - Investors who purchased Petco securities between January 14, 2021, and June 5, 2025, may be eligible to participate in the class action [1][3]. - Shareholders interested in serving as lead plaintiffs can contact the firm, but participation is not required to be eligible for recovery [3]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is successful [4].

Core Viewpoint - A class action lawsuit has been filed against Red Cat Holdings, Inc. for allegedly misleading investors regarding its production capacity and the value of its contracts, particularly the U.S. Army's Short Range Reconnaissance Program [1][2][3] Allegations - The complaint states that Red Cat Holdings overstated the production capacity of its Salt Lake City Facility and the overall value of the SRR Contract [2] - Kerrisdale Capital's report claims the SRR Contract is valued between $20 million and $25 million, contrary to Red Cat's representations [3] - Following the report, Red Cat's stock price dropped by $2.35 per share, or 21.54%, closing at $8.56 on January 17, 2025 [3] Class Action Participation - Shareholders interested in serving as lead plaintiffs have until July 22, 2025, to apply for this status [4] - Participation in the class action is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Company Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance [5]

Group 1 - A class action has been filed against Petco Health and Wellness Company, Inc. for misleading investors regarding its business prospects during the period from January 14, 2021, to June 5, 2025 [1][2] - Allegations include that Petco's pandemic-related growth was unsustainable and that the company overstated its ability to deliver sustainable, profitable growth [2] - The complaint highlights that the true scope of issues affecting Petco's business model and sales metrics was downplayed by the defendants [2] Group 2 - Shareholders may participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff [3] - The representation in the class action is on a contingency fee basis, meaning shareholders pay no fees or expenses [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Allegations - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. - Specific allegations include that the severity of adverse events would attract regulatory scrutiny and increase risks surrounding the therapy's approvals [2]. Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3]. - On June 15, 2025, after disclosing a second patient death due to acute liver failure and announcing a suspension of shipments for non-ambulatory patients, the stock fell by $15.24, or 42.12%, closing at $20.91 [3]. - The FDA's investigation announcement on June 24, 2025, regarding the risk of acute liver failure led to an additional stock price decline of $1.52, or 8.01%, closing at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file a motion by August 25, 2025, although participation is not required to be eligible for recovery [5].

SAN DIEGO, June 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025.  Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations th ...

Group 1 - A class action has been filed against Reddit, Inc. on behalf of investors who purchased securities between October 29, 2024, and May 20, 2025 [1] - The allegations include that Reddit misled investors about reduced user traffic due to changes in Google Search's algorithm and features, which led to a significant decline in traffic to the Reddit website [2] - The complaint states that the defendants were aware that increased search queries for "Reddit" were due to users finding answers directly on Google, rather than intending to visit Reddit, which contributed to the misleading public statements [2] Group 2 - Shareholders may be eligible to participate in the class action and can contact Robbins LLP for more information on serving as lead plaintiff [3] - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur fees or expenses [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Reckitt Benckiser Group PLC American Depository Shares (ADSs) between January 13, 2021, and July 28, 2024, alleging that the company misled investors regarding the safety of its Enfamil baby formula [1][2]. Allegations - The lawsuit claims that Reckitt failed to inform investors and consumers about the increased risk of necrotizing enterocolitis (NEC) in preterm infants consuming its cow's milk-based formula, Enfamil, and the potential negative impact on sales and legal exposure [2]. - A jury in Illinois awarded $60 million in a case against Mead Johnson, finding negligence related to the same NEC risk, which led to a significant drop in Reckitt's ADS price [3]. - Following a similar case in Missouri, where Abbott Laboratories was found liable for NEC, Reckitt's ADS price also experienced a notable decline [4]. Next Steps - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 4, 2025, with the option to remain an absent class member if they choose not to take action [5].

Core Viewpoint - A class action has been filed against 3D Systems Corporation for allegedly misleading investors about its business prospects, particularly regarding customer spending and revenue impacts from updated milestone criteria in its Regenerative Medicine Program [1][2]. Financial Performance - On March 26, 2025, 3D Systems announced disappointing financial results for Q4 and full-year 2024, leading to a stock price drop of $0.57 per share, or 20.96%, closing at $2.15 on March 27, 2025 [3]. - For Q1 2025, 3D Systems reported revenue of $94.5 million, down 8% year-over-year, missing consensus estimates of $99.5 million. The company also reported a net loss of $37 million, or $0.28 per share, more than doubling the $16 million loss from Q1 2024 [4]. - The adjusted loss per share was $0.21, worse than the consensus estimate of a loss of $0.14 per share, and adjusted EBITDA showed a loss of $23.9 million, worsening from a $20.1 million loss in Q1 2024 [4]. - The company withdrew its full-year 2025 outlook due to prolonged softness in customer capital spending and macroeconomic uncertainty, resulting in a further stock price decline of $0.68 per share, or 26.6%, closing at $1.87 on May 13, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against Civitas Resources, Inc. for allegedly misleading investors about its production capabilities and financial condition during the specified class period [1][2]. Allegations - Civitas is accused of failing to disclose significant reductions in oil production expected in 2025 due to declines after a production peak in Q4 2024 and a low TIL count at the end of 2024 [2]. - The company would need to acquire additional acreage and development locations to increase oil production, which would incur significant debt and potentially require selling corporate assets [2]. - Financial conditions would necessitate disruptive cost-reduction measures, including a significant workforce reduction [2]. - The company's business and financial prospects, as well as operational capabilities, were allegedly overstated [2]. Stock Price Impact - Following the revelation of these issues on February 24, 2025, Civitas's stock price dropped by $8.95 per share, representing a decline of over 18%, closing at $40.35 per share on February 25, 2025 [2]. Class Action Participation - Shareholders may be eligible to participate in the class action, with a deadline to file as lead plaintiff by July 1, 2025 [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3]. Company Background - Civitas Resources, Inc. is an independent exploration and production company focused on crude oil and liquids-rich natural gas in the Denver-Julesburg Basin in Colorado and the Permian Basin in Texas and New Mexico [1].